Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + 6-thioguanine
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral, Intrathecal, Subcutaneous
01
Overview
Cytarabine + 6-thioguanine is a combination chemotherapy regimen consisting of two antimetabolite agents used primarily in the treatment of acute myeloid leukemia (AML) and other hematologic malignancies. Cytarabine (also known as Ara-C or cytosine arabinoside) is a pyrimidine nucleoside analog that inhibits DNA synthesis by incorporation into DNA and inhibition of DNA polymerase, leading to cell cycle arrest in the S-phase. 6-Thioguanine is a purine analog that interferes with de novo purine synthesis and incorporates into DNA and RNA, resulting in cytotoxicity through disruption of nucleic acid function. The combination exploits synergistic effects on rapidly dividing leukemic cells. This regimen has been used for induction, consolidation, and maintenance therapy in AML[1][2][4][5].
- Other names
- cytosine arabinoside + 6-thioguanineara-C + TGcytarabine + thioguanine
02
Targets
DNAIMPDH (Inosine-5'-monophosphate dehydrogenase 1)HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)PPAT (Amidophosphoribosyltransferase)
Beyond the preview
Go deeper on cytarabine + 6-thioguanine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + 6-thioguanine.